BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25521525)

  • 1. SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.
    Ceccherini E; Indovina P; Zamperini C; Dreassi E; Casini N; Cutaia O; Forte IM; Pentimalli F; Esposito L; Polito MS; Schenone S; Botta M; Giordano A
    J Cell Biochem; 2015 May; 116(5):856-63. PubMed ID: 25521525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SRC Family Kinase Inhibition in Ewing Sarcoma Cells Induces p38 MAP Kinase-Mediated Cytotoxicity and Reduces Cell Migration.
    Indovina P; Casini N; Forte IM; Garofano T; Cesari D; Iannuzzi CA; Del Porro L; Pentimalli F; Napoliello L; Boffo S; Schenone S; Botta M; Giordano A
    J Cell Physiol; 2017 Jan; 232(1):129-35. PubMed ID: 27037775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.
    Casini N; Forte IM; Mastrogiovanni G; Pentimalli F; Angelucci A; Festuccia C; Tomei V; Ceccherini E; Di Marzo D; Schenone S; Botta M; Giordano A; Indovina P
    Oncotarget; 2015 May; 6(14):12421-35. PubMed ID: 25762618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition.
    Cozzi M; Giorgi F; Marcelli E; Pentimalli F; Forte IM; Schenone S; D'Urso V; De Falco G; Botta M; Giordano A; Indovina P
    Cell Cycle; 2012 Mar; 11(5):1029-39. PubMed ID: 22333592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization.
    Indovina P; Giorgi F; Rizzo V; Khadang B; Schenone S; Di Marzo D; Forte IM; Tomei V; Mattioli E; D'Urso V; Grilli B; Botta M; Giordano A; Pentimalli F
    Oncogene; 2012 Feb; 31(7):929-38. PubMed ID: 21785466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
    Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
    J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
    Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
    Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells.
    Spreafico A; Schenone S; Serchi T; Orlandini M; Angelucci A; Magrini D; Bernardini G; Collodel G; Di Stefano A; Tintori C; Bologna M; Manetti F; Botta M; Santucci A
    FASEB J; 2008 May; 22(5):1560-71. PubMed ID: 18171692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.
    Laschi M; Bernardini G; Geminiani M; Manetti F; Mori M; Spreafico A; Campanacci D; Capanna R; Schenone S; Botta M; Santucci A
    Biofactors; 2017 Nov; 43(6):801-811. PubMed ID: 28786551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
    Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
    Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.
    Carraro F; Naldini A; Pucci A; Locatelli GA; Maga G; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Modugno M; Tintori C; Manetti F; Botta M
    J Med Chem; 2006 Mar; 49(5):1549-61. PubMed ID: 16509573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
    Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
    Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
    Dreassi E; Zizzari AT; Mori M; Filippi I; Belfiore A; Naldini A; Carraro F; Santucci A; Schenone S; Botta M
    Eur J Med Chem; 2010 Dec; 45(12):5958-64. PubMed ID: 20970221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
    Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
    Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
    Bartscht T; Lehnert H; Gieseler F; Ungefroren H
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):221-30. PubMed ID: 22699812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.
    Zhang L; Yang Z; Sang H; Jiang Y; Zhou M; Huang C; Huang C; Wu X; Zhang T; Zhang X; Wan S; Zhang J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1541-1552. PubMed ID: 34238111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
    Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
    Hingorani P; Zhang W; Gorlick R; Kolb EA
    Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model.
    Vignaroli G; Iovenitti G; Zamperini C; Coniglio F; Calandro P; Molinari A; Fallacara AL; Sartucci A; Calgani A; Colecchia D; Mancini A; Festuccia C; Dreassi E; Valoti M; Musumeci F; Chiariello M; Angelucci A; Botta M; Schenone S
    J Med Chem; 2017 Jul; 60(14):6305-6320. PubMed ID: 28650650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Src family kinases differentially influence glioma growth and motility.
    Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
    Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.